A Phase IIb Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Co-administration of AZD9550 and AZD6234 in Participants Living With Obesity or Overweight with Co-morbidity (ASCEND)
The ASCEND study investigates the efficacy and tolerability of a 36-week treatment with placebo or AZD9550 in combination with AZD6234 to assess combined effects on weight loss.
You may be eligible for the study if you meet the following criteria.
If eligible for the study, your participation is expected to last approximately 47weeks.
Please contact CDH Research Institute on 07 5408 0900 for additional information or use the email link below. You can also share details of this study to social media via the links below?
Clinical trials are important because they serve as the foundation for most medical advances.
